Sitoiganap (autologous glioma tumor cell lysates (inactivated);allogeneic glioma tumor cell lysates (inactivated);allogeneic glioma tumor cells (inactivated);autologous glioma tumor cells (inactivated))
- Region
- 🇪🇺 EU
- Active substance
- autologous glioma tumor cell lysates (inactivated);allogeneic glioma tumor cell lysates (inactivated);allogeneic glioma tumor cells (inactivated);autologous glioma tumor cells (inactivated)
- Company
- Epitopoietic Research Corporation-Belgium (E.R.C.)
- Status
- Application withdrawn
- Therapeutic area
- Glioma; Gliosarcoma
- Application
- EMEA/H/C/003693
- ATC
- L01XX
- Official record
- www.ema.europa.eu
Indication
Treatment of glioma.
Regulatory milestones
No milestones recorded in the last year.
Follow Sitoiganap
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.